© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Genitourinary Cancers
Delivering Optimal Outcomes in Prostate Cancer Despite Adverse Events
March 25, 2020
Eugene B. Cone, MD, discusses the strategies for treating patients with prostate cancer who develop adverse events, such as cardiac events and immune-related events.
A 75-Year-Old Man With Metastatic Castrate-Resistant Prostate Cancer
March 24, 2020
A 75-Year-Old Man With Metastatic Castrate-Resistant Prostate Cancer
Barriers Impact Receipt of Life-Extending Treatment in High-Risk Prostate Cancer for Younger Patients
March 24, 2020
A significant percentage of younger men with high-risk prostate cancer who display minimal comorbidities continue to receive nondefinitive therapy (NDT), despite research that has demonstrated local therapy is more beneficial in this patient population, according to findings from a study published in JAMA Oncology show. A number of reasons for this have been identified, including insurance status and race/ethnicity.
South Carolina Oncology Practice Continues Cautious Operation Amidst the COVID-19 Pandemic
March 23, 2020
In an interview with Targeted Oncology, Kashyap Patel, MD, discussed the COVID-19 pandemic and the implementation of new precautions in his practice as the number of COVID-19 infected persons rises in the state.
Enzalutamide Plus Standard Treatment May Extend Remission in High-Risk Recurrent Prostate Cancer
March 23, 2020
The addition of 6 months of oral daily enzalutamide to standard salvage radiation and hormone therapy is safe and may improve prostate cancer remission rates at 2 and 3 years postoperatively among patients with high-risk disease, according to a recent paper in European Urology Oncology.
Before Starting Targeted Therapy for Prostate Cancer, Determine Cardiovascular Risk
March 21, 2020
Elderly patients with advanced prostate cancer should be evaluated for preexisting cardiovascular diseases before taking oral androgen signaling inhibitors by a multidisciplinary team, includ­ing a cardiologist, according to a recent retro­spective study. Investigators at Thomas Jeffer­son University in Philadelphia, Pennsylvania, demonstrated that after receiving abiraterone acetate or enzalutamide, these patients had higher rates of short-term mortality than similar patients without CVDs.
Benefit of PARP Inhibitors May Extend to Certain Tumors With IDH Mutations
March 21, 2020
Patients harboring IDH1/2 muta­tions may receive benefit by the use of PARP inhibitors, with investigators initi­ating clinical trials in patients across multiple different tumor types to determine the efficacy of this strategy.
Pembrolizumab Monotherapy Elicits Responses in Patients With Advanced Rare Cancers
March 20, 2020
Treatment with pembrolizumab demonstrated antitumor activity along with tolerable toxicity in patients with 4 different rare and hard-to-treat malignancies, according to results from a phase II study led by The University of Texas MD Anderson Cancer Center researchers and published in the Journal for ImmunoTherapy of Cancer.
COSMIC-021 Trial Shows Efficacy and Tolerability in mCRPC
March 17, 2020
Neeraj Agarwal, MD, discusses the efficacy of cabozantinib and atezolizumab in the COSMIC-021 study.
Healthy People 2020 Initiative Demonstrates Progress on the Status of Cancer in the US
March 17, 2020
To help assess the advances the United States has made in decreasing cancer-related deaths, a collective of public health bodies found that monitoring trends in cancer risk, screening test use, and mortality is informative. A report published in Cancer shows that progress has been made in recent years, but there is more work to be done.